据悉，CoreWeave是首家获得英伟达Vera CPU芯片独立单元访问权的客户。 此前有传言称英伟达实际上正在考虑成为云服务提供商，与那些大量购买其芯片的客户竞争。但这一想 法被搁置，因为要在AWS和其他大型服务提供商面前获得立足点需要大量投资。 Q&A 英伟达继续发挥其雄厚的财务实力，这次向GPU云服务提供商CoreWeave投资20亿美元。 公司表示，这笔投资体现了英伟达"对CoreWeave业务、团队和增长战略的信心，CoreWeave是构建在英 伟达基础设施之上的云平台"。 CoreWeave并不是唯一一家基于英伟达基础设施构建业务的公司，亚马逊、微软、谷歌、甲骨文，以及 Lambda Labs、Crusoe、RunPod等专用GPU云服务提供商也是如此。 在这笔交易达成之前，英伟达已经拥有CoreWeave约6%的股份，这次额外投资预计将英伟达的总持股比 例提升至约9%。英伟达绝不打算成为被动股东，公司表示计划执行以下行动： 建设由CoreWeave开发和运营的AI工厂，使用英伟达技术。 利用英伟达的财务实力，加速CoreWeave在土地、电力和基础设施采购方面的进程，以建设AI工厂。 测试和验证 ...

Amid recent market turmoil, Nvidia Corporation ( NVDA ) has remained astonishingly range-bound on its sideways trajectory between roughly $150 and $200 since last summer. Having hinted at high valuation, multiple expansion, and the factExcellent academic Finance background and Finance professional with over five years of cumulative experience in Consulting & Audit Firms including a professional Valuation position, FP&A and Controlling positions, and Financial writing.My approach is mostly value-oriented. Ho ...

来源：滚动播报 英伟达股价在连跌五日后上涨2%。 ...

Group 1 - Alphabet announced a capital expenditure of $175 billion to $185 billion for 2026, which was followed by Amazon revealing a significantly higher capital expenditure of $200 billion for the same year, exceeding Wall Street's expectation of $150 billion [1] - Amazon's CEO Andy Jassy emphasized strong demand for existing products and highlighted "pioneering opportunities" in AI, semiconductors, robotics, and low Earth orbit satellites, despite investor concerns over high capital spending [1] - Amazon's stock fell over 8% in pre-market trading following the announcement, indicating investor apprehension regarding the high capital expenditure [1] Group 2 - Marvell Technology is identified as a potential beneficiary of Amazon's capital spending, as it produces Trainium processors for the company [1] - AT&T is expected to benefit from a partnership with Amazon, utilizing Amazon's low Earth orbit satellite internet services to provide stable network connections in signal blind spots across the U.S. [2] - Nvidia and AMD are also potential beneficiaries due to their established partnerships with Amazon, supplying chip products to meet the computing needs in cloud computing and AI [2]

智通财经APP获悉，受人工智能(AI)发展及芯片技术全面渗透经济各领域的双重驱动，全球半导体行业 今年营收将首次突破1万亿美元关口。 他表示："行业的周期性波动客观存在，且未来仍将持续，但整体市场的蛋糕正在不断做大。" 近年来，中美贸易摩擦为半导体行业蒙上阴影，美国政府此前不断加码芯片出口管制措施。但Neuffer 称，目前相关管制政策已出现松动迹象。 他还提出，美国半导体行业若想实现长期稳健发展，一方面需要政府加大对研发领域的支持力度，另一 方面也需推进移民政策改革，以此吸引并留住海外高端人才。 作为各类设备"算力大脑"的逻辑芯片，2025年营收大幅增长40%，达到3019亿美元;负责计算机数据存储 与管理的存储芯片销售额也增长35%，至2231亿美元。从区域市场来看，亚太、美洲、欧洲及中国市场 均实现增长，仅日本市场出现下滑。 Neuffer指出，半导体市场虽仍将延续其特有的繁荣与萧条交替的周期波动，但长期向上的发展趋势已 确立无疑。 美国半导体行业协会(SIA)数据显示，2025年全球半导体行业总销售额达7917亿美元，预计2026年将再 度飙升26%，实现新一轮跃升。该协会首席执行官John Neuf ...

纬创CEO林建勋透露，该美国制造基地将于2026年上半年正式量产。部分产能将用于支持英伟达的计划 ——未来四年在美国建设价值高达5000亿美元的AI服务器生产线。 去年4月，英伟达宣布计划在得克萨斯州建设超级计算机制造基地，其中休斯顿项目与富士康合作，达 拉斯项目则与纬创携手推进。 该公司去年曾表示，其为英伟达新建的美国生产基地将于2026年投产，并正在与其他潜在客户接洽。 智通财经APP获悉，中国台湾省电子制造企业纬创资通(Wistron)董事长林宪铭周五表示，人工智能(AI) 并非泡沫，预计2026年公司AI相关订单的增长幅度将超过去年。该公司也是英伟达(NVDA.US)的供应 商。林宪铭在台北向记者表示："我们认为AI确实能赋能所有行业，因此并非泡沫，而是一个新时代的 开端，崭新的AI时代正在到来。" 他还补充称，纬创的订单情况良好，已排至2027年，且今年订单量较去年将实现"显著"增长。 ...

英伟达股价在连跌五日后，盘前上涨2%。 来源：滚动播报 ...

Core Viewpoint - Artificial intelligence is not a bubble, and AI-related order growth in 2026 will exceed that of the previous year according to Simon Lin, chairman of Wistron [1] Company Insights - Wistron, a Taiwanese electronics manufacturer, is optimistic about the growth of AI-related orders in the coming years [1]

Market Analysis by covering: Euro US Dollar, US Dollar Japanese Yen, US Dollar Swiss Franc, Euro British Pound. Read 's Market Analysis on Investing.com ...

Group 1 - The article provides a market analysis of Pfizer Inc., highlighting its recent performance and strategic initiatives in the pharmaceutical industry [1] - Pfizer's revenue for the last quarter reached $22.6 billion, reflecting a 47% decrease compared to the same period last year, primarily due to reduced demand for COVID-19 vaccines and treatments [1] - The company is focusing on diversifying its product portfolio and investing in new drug development to offset declining revenues from pandemic-related products [1] Group 2 - Pfizer's research and development expenses increased by 10% year-over-year, amounting to $3.5 billion, indicating a commitment to innovation and long-term growth [1] - The company has several key drug candidates in late-stage clinical trials, which could significantly impact future revenue streams if approved [1] - Pfizer's stock performance has been volatile, with a current market capitalization of approximately $200 billion, reflecting investor concerns over its post-pandemic strategy [1]